Recently, immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting PD‐1/PD‐L1, has emerged as a promising approach in melanoma treatment.[2] In 2014, Nivolumab became the first PD‐1 inhibitor approved by the FDA for the treatment of melanoma. The gene discussed is CD274; the disease is melanoma.